Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
NanoRepro AG is a biotechnology company that specializes in the development, manufacturing, and distribution of rapid diagnostic tests. These tests are primarily used in personal and home care health sectors. NanoRepro's portfolio includes products that target infectious diseases, fertility monitoring, and preventive health measures, making medical diagnostics more accessible and convenient for the general public. With a strong emphasis on innovation and precision, the company’s offerings are designed to deliver quick results, enabling timely and effective healthcare decisions. Operating primarily in Europe, NanoRepro AG plays an important role in the biotechnological landscape by reducing the gap between professional healthcare facilities and individual users. This enhances consumer autonomy in health management and contributes to the broader goal of preventative health by allowing early detection and management of various health conditions.
The business is unprofitable at the operating level (-74.23% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 43.2% YoY with margins expanding 62.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€5M
▲ +43.2% YoY
Net Income (TTM)
-€2M
▲ +56.3% YoY
Op. Margin
-74.23%
▲ +62.6pp YoY
ROIC
-6.94%
▲ +1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€9M
▲ +192.1% YoY
Op. Cash Flow (TTM)
€10M
▲ +196.1% YoY
Net Debt
-€9M
Net Cash Position
Cash & Equiv.
€9M
3Y CAGR: -69.4%
3Y CAGR: +4.8%
Continue Research